Q-omics provides the consensus-scored RNASE7 profile across patient tissues and cancer cell-line models. RNASE7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNASE7 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, RNASE7 RNA expression shows 13,509 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUSC, and THYM as cancer lineages where RNASE7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE7 survival associations across molecular data types. RNASE7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE7 RNA expression–survival associations across cancer types. High RNASE7 expression shows unfavorable associations in UVM, THCA, SCLC, MESO and READ, but favorable associations in ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNASE7 RNA expression.
This table summarizes RNASE7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RNASE7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE7 shows lower tumor expression in KIRC and BRCA and higher tumor expression in LUSC, BLCA, COAD and HNSC. The LUSC box plot shows higher RNASE7 RNA expression in tumor versus normal tissue (log2 FC = +2.608, t-test p < 0.001).
This table shows molecular features associated with RNASE7 in patient tissues and cancer cell lines. In patient samples, RNASE7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
